CIK 0001816736 · Large accelerated filer
Disc Medicine, Inc.
Sign in to watch- Ticker
- IRON
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 851612845
- Phone
- (617) 674-9274
- Business address
- 321 ARSENAL STREET, SUITE 101, WATERTOWN, MA, 02472
- Former names
- Gemini Therapeutics, Inc. /DE, FS Development Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $14,489,047
- in 7 filings, $12.6M under 10b5-1 plans
Net −$14,489,047. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-15 | Quisel John D Chief Executive Officer | Option exercise | +36,000 | $1.01 | $36K | 262,064 |
| 2026-09-15 | Quisel John D Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −36,000 | 150,120 | ||
| 2026-08-17 | Quisel John D Chief Executive Officer | Option exercise 10b5-1 | +33,000 | $13.50 | $446K | 259,064 |
| 2026-08-17 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −8,400 | $78.11 | $656K | 250,664 |
| 2026-08-17 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −12,712 | $79.20 | $1.0M | 237,952 |
| 2026-08-17 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −11,888 | $79.84 | $949K | 226,064 |
| 2026-08-17 | Quisel John D Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −33,000 | 91,586 | ||
| 2026-07-13 | Quisel John D Chief Executive Officer | Option exercise 10b5-1 | +25,584 | $9.86 | $252K | 251,648 |
| 2026-07-13 | Quisel John D Chief Executive Officer | Option exercise 10b5-1 | +7,416 | $13.50 | $100K | 259,064 |
| 2026-07-13 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −9,704 | $74.27 | $721K | 249,360 |
| 2026-07-13 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −16,896 | $74.95 | $1.3M | 232,464 |
| 2026-07-13 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −6,400 | $76.05 | $487K | 226,064 |
| 2026-07-13 | Quisel John D Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,584 | 15,791 | ||
| 2026-07-13 | Quisel John D Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,416 | 124,586 | ||
| 2026-06-18 | Quisel John D Chief Executive Officer | Option exercise 10b5-1 | +34,000 | $9.86 | $335K | 260,064 |
| 2026-06-18 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −22,927 | $69.92 | $1.6M | 237,137 |
| 2026-06-18 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −9,522 | $70.70 | $673K | 227,615 |
| 2026-06-18 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −1,551 | $71.61 | $111K | 226,064 |
| 2026-06-18 | Quisel John D Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −34,000 | 41,375 | ||
| 2026-02-17 | Quisel John D Chief Executive Officer | Sale | −13,264 | $62.86 | $834K | 226,064 |
Page 1 of 3 · 55 trades